$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924015209 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$91.00K	$73.00K
YoY Change	-66.17%	-31.78%
Cost Of Revenue	$18.00K	$16.00K
YoY Change	-72.73%	220.0%
Gross Profit	$73.00K	$57.00K
YoY Change	-64.04%	-44.12%
Gross Profit Margin	80.22%	78.08%
Selling, General & Admin	$3.247M	$3.354M
YoY Change	-15.82%	-0.53%
% of Gross Profit	4447.95%	5884.21%
Research & Development	$4.150M	$5.869M
YoY Change	-37.26%	-20.64%
% of Gross Profit	5684.93%	10296.49%
Depreciation & Amortization	$414.0K	$420.0K
YoY Change	-6.33%	4.48%
% of Gross Profit	567.12%	736.84%
Operating Expenses	$4.150M	$5.869M
YoY Change	-37.26%	-20.64%
Operating Profit	-$7.400M	-$9.200M
YoY Change	-28.41%	-14.28%
Interest Expense	-$991.0K	$1.244M
YoY Change	-189.76%	16.7%
% of Operating Profit
Other Income/Expense, Net	$606.0K	-$1.848M
YoY Change	-104.09%	78.03%
Pretax Income	-$6.785M	-$11.08M
YoY Change	-73.01%	-5.86%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.785M	-$11.08M
YoY Change	-73.01%	-5.86%
Net Earnings / Revenue	-7456.04%	-15178.08%
Basic Earnings Per Share	-$1.06	-$0.09
Diluted Earnings Per Share	-$1.06	-$0.09
COMMON SHARES
Basic Shares Outstanding	128.4M	128.4M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.68M	$27.91M
YoY Change	-55.97%	51.34%
Cash & Equivalents	$21.68M	$21.73M
Short-Term Investments	$0.00	$6.178M
Other Short-Term Assets	$911.0K	$832.0K
YoY Change	3.17%	-13.51%
Inventory	$37.00K	$37.00K
Prepaid Expenses
Receivables	$0.00	$64.00K
Other Receivables	$1.217M	$1.442M
Total Short-Term Assets	$27.91M	$32.11M
YoY Change	-47.71%	29.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.36M	$12.90M
YoY Change	-14.25%	-14.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$58.00K	$58.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$12.42M	$12.96M
YoY Change	-14.19%	-13.99%
TOTAL ASSETS
Total Short-Term Assets	$27.91M	$32.11M
Total Long-Term Assets	$12.42M	$12.96M
Total Assets	$40.33M	$45.07M
YoY Change	-40.56%	12.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.066M	$1.645M
YoY Change	26.0%	170.56%
Accrued Expenses	$5.927M	$3.905M
YoY Change	37.9%	-34.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$5.042M
YoY Change
Long-Term Debt Due	$20.45M	$14.99M
YoY Change	32888.71%	52.58%
Total Short-Term Liabilities	$28.07M	$26.19M
YoY Change	389.43%	55.16%
LONG-TERM LIABILITIES
Long-Term Debt	$7.013M	$7.085M
YoY Change	-72.86%	-57.38%
Other Long-Term Liabilities	$5.752M	$7.535M
YoY Change	-60.97%	-6.0%
Total Long-Term Liabilities	$12.77M	$14.62M
YoY Change	-68.54%	-40.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.07M	$26.19M
Total Long-Term Liabilities	$12.77M	$14.62M
Total Liabilities	$40.83M	$40.81M
YoY Change	-11.83%	-1.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$260.6M	-$253.8M
YoY Change	13.26%	23.8%
Common Stock	$1.000K	$13.00K
YoY Change	-92.31%	62.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$504.0K	$4.264M
YoY Change
Total Liabilities & Shareholders Equity	$40.33M	$45.07M
YoY Change	-40.56%	12.99%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$6.785M	-$11.08M
YoY Change	-73.01%	-5.86%
Depreciation, Depletion And Amortization	$414.0K	$420.0K
YoY Change	-6.33%	4.48%
Cash From Operating Activities	-$6.356M	-$7.100M
YoY Change	-9.47%	-22.83%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$11.00K
YoY Change	-105.13%	-96.04%
Acquisitions
YoY Change
Other Investing Activities	$6.250M	$82.00K
YoY Change		-98.36%
Cash From Investing Activities	$6.248M	$71.00K
YoY Change	15920.51%	-98.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	28.00K	-$19.00K
YoY Change	-99.93%	-100.41%
NET CHANGE
Cash From Operating Activities	-6.356M	-$7.100M
Cash From Investing Activities	6.248M	$71.00K
Cash From Financing Activities	28.00K	-$19.00K
Net Change In Cash	-80.00K	-$7.089M
YoY Change	-100.26%	-6544.55%
FREE CASH FLOW
Cash From Operating Activities	-$6.356M	-$7.100M
Capital Expenditures	$2.000K	$11.00K
Free Cash Flow	-$6.358M	-$7.111M
YoY Change	-8.94%	-24.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128433721
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128433721
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128422851
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128422851
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	27000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	334000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128433721
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128422851
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	01-39834
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive, Suite G50
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
CY2024Q1	dei	City Area Code CityAreaCode	801
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	676-9695
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128433721
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21732000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28821000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6178000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6179000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	64000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	143000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	37000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	37000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4100000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3672000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	32111000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	38852000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4046000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4168000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8854000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9263000	usd
CY2024Q1	us-gaap	Assets Assets	45069000	usd
CY2023Q4	us-gaap	Assets Assets	52341000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1645000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1504000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3905000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3720000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	599000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	576000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	14987000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	14627000	usd
CY2024Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5042000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4876000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26185000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25330000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4720000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4903000	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	1820000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1894000	usd
CY2024Q1	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	5265000	usd
CY2023Q4	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	5258000	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2790000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1481000	usd
CY2024Q1	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	22000	usd
CY2023Q4	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	75000	usd
CY2024Q1	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	3000	usd
CY2023Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	10000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	40805000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38951000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	257914000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	255901000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253803000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242723000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	140000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	199000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4264000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13390000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45069000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52341000	usd
CY2024Q1	us-gaap	Revenues Revenues	73000	usd
CY2023Q1	us-gaap	Revenues Revenues	107000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	16000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	5000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5869000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7395000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3420000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3439000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	9305000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	10839000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9232000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10732000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	359000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	172000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1244000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1066000	usd
CY2024Q1	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	-0	usd
CY2023Q1	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	399000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1309000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	usd
CY2024Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	53000	usd
CY2023Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-55000	usd
CY2024Q1	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	7000	usd
CY2023Q1	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	-7000	usd
CY2024Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	286000	usd
CY2023Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	314000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1848000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1038000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11080000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11770000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11080000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11770000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-4000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	14000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-55000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-59000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	18000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11139000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11752000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128427231
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76049665
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13390000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2013000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-55000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11080000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4264000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3237000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4665000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2223000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11770000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1627000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11080000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11770000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	420000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	402000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	122000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	108000	usd
CY2024Q1	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	0	usd
CY2023Q1	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	399000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1309000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2024Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	53000	usd
CY2023Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-55000	usd
CY2024Q1	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	7000	usd
CY2023Q1	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	-7000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2013000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2223000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	367000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	250000	usd
CY2024Q1	clnn	Noncash Interest Income Expense On Marketable Securities NoncashInterestIncomeExpenseOnMarketableSecurities	81000	usd
CY2023Q1	clnn	Noncash Interest Income Expense On Marketable Securities NoncashInterestIncomeExpenseOnMarketableSecurities	-0	usd
CY2024Q1	clnn	Noncash Interest Income Expense On Notes Payable NoncashInterestIncomeExpenseOnNotesPayable	-91000	usd
CY2023Q1	clnn	Noncash Interest Income Expense On Notes Payable NoncashInterestIncomeExpenseOnNotesPayable	-82000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-79000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-126000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	45000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	428000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	581000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	141000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2406000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	185000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2070000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-160000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-138000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7082000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9218000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6168000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	6250000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	278000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4722000	usd
CY2024Q1	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	0	usd
CY2023Q1	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	4266000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	19000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	28000	usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	350000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-19000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4588000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-59000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7089000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	110000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28879000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18390000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21790000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18500000	usd
CY2024Q1	us-gaap	Cash Cash	21732000	usd
CY2023Q1	us-gaap	Cash Cash	18442000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21790000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18500000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	784000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	982000	usd
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9200000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10700000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253800000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242700000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	27900000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	35000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7100000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9200000	usd
CY2023	clnn	Minimum Cash Balance For Loan Covenant MinimumCashBalanceForLoanCovenant	5000000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results <em style="font: inherit;"> may </em>differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"> </p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentrations of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is held in financial institutions and amounts on deposit <em style="font: inherit;"> may </em>at times exceed federally insured limits. We have <em style="font: inherit;">not</em> experienced any losses on our deposits of cash and do <em style="font: inherit;">not</em> believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"> </p>
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	23000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	23000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6300000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1208000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1236000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1132000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5000000	usd
CY2024Q1	us-gaap	Supplies Supplies	1826000	usd
CY2023Q4	us-gaap	Supplies Supplies	1909000	usd
CY2024Q1	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	1442000	usd
CY2023Q4	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	1195000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	832000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	568000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4100000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3672000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	16133000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	16150000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	7279000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	6887000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8854000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9263000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	420000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	402000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1093000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	649000	usd
CY2024Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2628000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2120000	usd
CY2024Q1	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	746000	usd
CY2023Q4	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	481000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	531000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1119000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3905000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3720000	usd
CY2024Q1	clnn	Number Of Real Estate Leases NumberOfRealEstateLeases	3	pure
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	469000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	449000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	167000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	187000	usd
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.11	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.11	pure
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y1M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M24D
CY2024Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	7000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	789000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1045000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	7000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7152000	usd
CY2024Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	-0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1833000	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	7000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5319000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	599000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4720000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	20000	usd
CY2024Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	254000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	253000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	53000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	50000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	329000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	307000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	303000	usd
CY2024Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	-0	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	6000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	19000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	28000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	16927000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	16915000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2223000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11039000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11546000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-41000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-224000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11080000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11770000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2013000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2223000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2013000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21846388
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.26
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	302000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	280070
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.44
CY2024Q1	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y11M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	141124
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.33
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21985334
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.22
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	568000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12511524
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.55
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M14D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	567000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	21985334
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.22
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	568000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.99
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9999	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0404	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	10870
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.15
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y2M23D
CY2024Q1	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	22000	usd
CY2024Q1	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	3000	usd
CY2023Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	75000	usd
CY2023Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	10000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128433721
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128422851
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	105432083
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	105432083
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11080000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11770000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128427231
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76049665
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	136510399
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29819656
CY2018Q3	clnn	Related Party Transaction Royalty Fee Rate For Revenues RelatedPartyTransactionRoyaltyFeeRateForRevenues	0.03	pure

Files In Submission

Name	View Source	Status
0001437749-24-015209-index-headers.html	Edgar Link	pending
0001437749-24-015209-index.html	Edgar Link	pending
0001437749-24-015209.txt	Edgar Link	pending
0001437749-24-015209-xbrl.zip	Edgar Link	pending
clnn-20240331.xsd	Edgar Link	pending
clnn20240331c_10q.htm	Edgar Link	pending
clnn-20240331_cal.xml	Edgar Link	unprocessable
clnn-20240331_def.xml	Edgar Link	unprocessable
clnn-20240331_lab.xml	Edgar Link	unprocessable
clnn-20240331_pre.xml	Edgar Link	unprocessable
clnn20240331c_10q_htm.xml	Edgar Link	completed
ex_622058.htm	Edgar Link	pending
ex_622059.htm	Edgar Link	pending
ex_622060.htm	Edgar Link	pending
ex_622061.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
newpipeline.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2024 Q2 Form 10-Q Financial Statement

#000143774924015209 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2024 Q2 Form 10-Q Financial Statement

#000143774924015209 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn